ClinicalTrials.gg
Enrolling by invitationNCT06168435eIMPAQcUpdated Nov 19, 2026

e-IMPAQc Systematic Assessment of Patient Reported Outcomes in Cancer Care

An interventional study of eIMPAQc in Cancer, sponsored by St. Mary's Research Center, Canada. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by St. Mary's Research Center, Canada · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Nov 2020, registered Aug 2023).
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Purpose: The Electronic Implementation of Patient and Caregiver Reported Outcomes across cancer centres in Quebec project, or e-IMPAQc, was launched in 2017. e-IMPAQc's goal is to actively engage patients, their caregivers, healthcare professionals (HCPs), managers, policy makers, researchers and IT personnel to co-develop, implement, and evaluate an evidence-informed electronic patient-reported outcomes (e-PRO) screening and management program across Quebec.

Methods: e-IMPAQc built on the Improving Patient Experience and Health Outcomes Collaborative (iPEHOC) project, the first initiative in the province to implement e-PRO screening and was rolled out in three phases. e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard. Phase 1 included initiating change management and the co-development of the e-PRO algorithm with patients, their caregivers, HCPs, managers, policy makers, researchers and IT personnel (herein collectively referred as stakeholders) across seven cancer centres. The iPEHOC algorithm was used as a starting point given its successful implementation in one of the participating cancer centres for several years. Phase 1 also included feasibility work to establish a caregiver-reported outcomes (CROs) algorithm as well as the identification and configuration of appropriate electronic platforms on which to house e-IMPAQc. In Phase 2 the focus was on preparing for imminent implementation through workflow mapping and putting in place implementation support (e.g., site coordinators). A pilot of e-IMPAQc (excluding CROs) was also undertaken at one of the participating centres. In Phase 3, e-IMPAQc is being sequentially rolled out to as many cancer centres as possible and then evaluated. Qualitative and quantitative methods are used to document the process of implementation, patient and caregiver, and knowledge transfer (KT) outcomes.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • ePRO
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 500 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

St. Mary's Research Center, Canada is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving cancer care at designated center

Exclusion criteria

Exclusion Criteria:

  • Unable to speak English or French
  • Unable to use email and internet
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • No intervention
    Pre-implementation

    Outcomes collected in patient populations prior to roll-out of the eIMPAQc

  • Experimental
    Post-implementation

    Outcomes collected in patient populations after roll-out of eIMPAQc

    Other: eIMPAQc

Interventions

  • OthereIMPAQc

    e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.

06

What researchers measure

Primary outcomes

  1. Symptom severity

    Symptom severity as measured by the population-specific eIMPAQc symptom screening algorithm, including the Edmonton Symptom Assessment System Revised (ESAS-r) screening measures. Severity is measured on a scale of 0-10.

    Time frame: Baseline, 4 months

  2. Patient perception of communication with health care team

    6 item Clinician-patient communication subscale of the Primary Care Assessment Survey (PCAS), provides an overall score

    Time frame: Baseline, 4 months

  3. Patient activation

    13 items Patient Activation Measure provides an overall score

    Time frame: Baseline, 4 months

  4. Quality of life

    The EQ-5D-5L is used to measure health related, quality of life. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated on scale that describes the degree of problems in that area.

    Time frame: Bsaseline,4 months

  5. Emergency room visits

    Using hospital administrative data, we will report on the number of individual visits to the emergency room

    Time frame: In the 18 months following consent

  6. Survival

    Incidence of mortality

    Time frame: In the 18 months following consent

  7. Feasibility of using the eIMPAQc ePRO system in cancer care centres

    Feasibility of using the eIMPAQc symptom screening and management program will be measured using the following metrics: * Rates of consent to use eIMPAQc among eligible patients referred/invited to patriciate * Rates of administration and completion of the eIMPAQc ePRO screening processes * Number and timing of withdrawals * Number of eIMPAQc ePRO screenings that generate an alert and/or clinical action Metrics will be combined with qualitative data from semi-structured interviews with participants to provide an overall assessment of feasibility

    Time frame: Throughout the implementation period, over the course of each participants' 4-6 month follow-up period

  8. Acceptability of using the eIMPAQc ePRO system in cancer care centres

    Acceptability of the components of the eIMPAQc program will be assessed through a 40 item eIMPAQc acceptability questionnaire

    Time frame: Throughout the implementation period, over the course of each participants' 4-6 month follow-up period

  9. Satisfaction

    Measured using the 8 item Client Satisfaction Questionnaire (CSQ-8)

    Time frame: 4 months

07

Study locations

1 site
  • St. Mary's Research Centre
    Montreal, Quebec H3T1M5, Canada
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 73 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2024 → Dec 2026 and completion Dec 2024 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Dec 13, 2023
StartActual
Nov 3, 2020
Primary completionEst.
Dec 31, 2026was Dec 2024
CompletionEst.
Dec 31, 2026was Dec 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2024→Dec 31, 2026
Nov 19, 2026
Study completion
Dec 31, 2024→Dec 31, 2026
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Dec 31, 2024→Dec 31, 2026
    Study completion Dec 31, 2024→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06168435
Lead sponsor
St. Mary's Research Center, Canada
Responsible party
Sylvie Lambert (Principal Scientist, St. Mary's Research Center, Canada) — Principal investigator
First posted
Dec 13, 2023
Start date
Nov 3, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion